Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
12/2008
12/25/2008US20080319198 N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}methane-sulfonamide; trial and ventricular arrhythmias; pharmacokinetics; electrophysiological activity; lowering daily clinical dose, lengthening duration of action; side effect reduction
12/25/2008US20080319017 Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
12/24/2008CN101328151A Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
12/24/2008CN101328150A 新的苯并咪唑衍生物 New benzimidazole derivatives
12/24/2008CN100445276C Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
12/18/2008US20080312449 New Compounds
12/18/2008US20080312434 Process for imidazo [4,5-c] pyridin-4-amines
12/18/2008US20080312242 7-aryl-3, 9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
12/18/2008US20080312219 Biologically active methylene blue derivatives
12/18/2008DE60224400T2 Hepatitis c virus polymerase inhibitoren mit heterobicylischer struktur Hepatitis C virus polymerase inhibitors with heterobicylischer structure
12/17/2008EP1753736B1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
12/17/2008EP1282609B1 Piperazinedione compounds
12/17/2008EP1077943B1 Heterocyclic inhibitors of p38
12/17/2008CN101326217A Light protective additive based on organic/ inorganic hybrid polymer, method for its manufacture and use thereof
12/17/2008CN101323622A 4-biphenylsubstituted pyrazolidin-3,5-dione derivatives
12/17/2008CN100443469C 病毒聚合酶抑制剂 Viral polymerase inhibitors
12/11/2008US20080306107 Compounds
12/11/2008US20080306103 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
12/10/2008CN101318957A Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
12/10/2008CN101318956A Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
12/09/2008US7462614 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives
12/09/2008CA2352054C New amidino derivatives and their use as thrombin inhibitors
12/09/2008CA2294059C New amidino derivatives and their use as thrombin inhibitors
12/03/2008EP1997811A2 Indazole, benzoxazole and pyrazolopyridine derivatives as P38 kinase inhibitors
12/03/2008EP1997810A2 Indazole, benzoxazole and pyrazolopyridine derivatives for medical use
12/03/2008EP1997809A2 Indazole, benzoxazole and pyrazolopyridine derivatives for medical use
12/03/2008CN100439360C Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
12/03/2008CN100439333C Process for producing of enantiomerically-pure azetidein-2-carboxylic acid
12/03/2008CN100439320C Intermediates for preparation of arthropodicidal oxadiazines
12/02/2008US7459463 Crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a] pyridine-6-carboxamide mesylate salt
12/02/2008US7459460 Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
12/02/2008CA2469315C Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
12/02/2008CA2305548C Prostaglandin agonists and their use to treat bone disorders
11/2008
11/27/2008US20080293748 Thioxanthine Derivatives as Myeloperoxidase Inhibitors
11/27/2008US20080293743 (5S)-5-({[6-(2-cyclopropylpyrimidin-5-yl)-3,4-dihydroisoquinolin-2(1H)-yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione; asthma, chronic obstructive pulmonary disease
11/27/2008US20080293705 A1 adenosine receptor antagonists
11/27/2008US20080290034 Bridged macrocyclic module compositions
11/26/2008CN100436452C Pyrazole compounds useful as protein kinase inhibitors
11/25/2008US7456182 Phenylpiperazines
11/25/2008CA2385728C Novel photochromic naphthopyrans
11/25/2008CA2320182C Compositions containing organic compounds
11/20/2008US20080287685 Detomidine Hydrochloride Crystallization Method
11/20/2008US20080287674 Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade
11/20/2008US20080287444 Pyrazole compounds useful as protein kinase inhibitors
11/18/2008US7452913 Patterns of enzyme inhibitors formed by dissolving compounds and isolation by precipitation
11/18/2008US7452888 Quinoline and aza indole compounds having pharmacological activity, for example, 8-(4-Methyl-piperazin-1-yl)-3-phenylsulfonylquinoline; use in the treatment of CNS and other disorders
11/18/2008US7452883 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
11/18/2008CA2516557C Triazole compounds useful in therapy
11/18/2008CA2434682C Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
11/12/2008EP1990341A1 Triazolyl tropane derivatives as CCR5 modulators
11/12/2008CN101302204A Quinazolone compound, composition and application including the same
11/12/2008CN101302182A Virus polymerase inhibitors
11/12/2008CN101302180A 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
11/11/2008US7450293 Electrochromic salts, solutions, and devices
11/11/2008US7449478 Treatment of peroxisome proliferation activated receptor diseases such as diabetes, skin disorders or high blood pressure
11/11/2008US7449475 e.g. 2-{[(2S)-3-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-N-cyclopropylbenzamide; macrophage inflammatory protein (MIP)-1 alpha chemokine receptor modulator; antiinflammatory, antiproliferative agent, autoimmune diseases
11/06/2008US20080275252 Atipamezole Hydrochloride Crystallization Method
11/06/2008US20080275092 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
11/06/2008US20080275059 Novel physiologically active substances
11/06/2008US20080275041 3-[5-({4-[2-(Dipropylamino)ethyl]piperazin-1-yl}sulfonyl)pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride; Alzheimer's Disease, Parkinson's Disease, depression, schizophrenia, HIV, Down syndrome, bone disorders, alopecia
11/06/2008US20080275033 Administering Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy
11/05/2008EP1200424B1 C7 heterosubstituted acetate taxanes as antitumor agents
11/05/2008CN101298433A 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
11/05/2008CN100430396C 2-phenyl-substituted imidazo-triazone used as phosphodiesterase inhibitor
11/05/2008CN100430379C Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
11/04/2008CA2443449C Pyrazole derivatives for treating hiv
10/2008
10/30/2008US20080269216 Gastrointestinal disorders; irritable bowel syndrome
10/30/2008US20080269197 antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia
10/30/2008US20080269176 New Salts
10/30/2008US20080268033 Biologically active methylene blue derivatives
10/30/2008US20080267867 Imidazole, pyridine derivative silver complexes; nanofiber with radioactive transition metal, lanthanide, actinide; radiopharmaceutical peptide, polyamine, imaging and tumor treatment
10/29/2008CN101293869A Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases
10/29/2008CN101293867A Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors
10/29/2008CN100429208C Process for prepn. of racemic citalopram and/or S-or R-citalopram by separation of mixture of R-and S-citalopram
10/29/2008CN100429201C Heterocyclic compounds and methods of use thereof
10/28/2008US7442708 Inhibitors of basic fibroblast growth factors (FGFs); treating cancer, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, diabetic retinopathy, achondroplasia, hypochondoplasia, or thanathophoric dysplasia
10/28/2008US7442705 HIV replication inhibiting pyrimidines and triazines
10/28/2008US7442702 Prostaglandin agonists
10/28/2008CA2342102C Tan-1057 derivatives
10/28/2008CA2262791C Amino acid ester containing azole antifungals
10/23/2008US20080262037 Piperidine Derivatives for the Treatment of Chemokine Mediated Disease
10/23/2008US20080261997 Use of aminoindazole derivatives for the inhibition of tau phosphorylation
10/23/2008US20080261960 Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents
10/22/2008EP1603562A4 Sulfonyl-amidino containing and tetrahydropyrimidino containing compounds as factor xa inhibitors
10/21/2008US7439251 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
10/21/2008CA2296732C Polyhydroxyalkylpyrazine derivatives, their preparation and medicines containing them
10/16/2008US20080255363 Novel Form of S-Omeprazole
10/16/2008US20080255207 5-Thioxo-1,5-Dihydro-2H-Pyrrol-2-One Derivatives As Liver X Receptor Modulators
10/16/2008US20080255199 Using 2-(((4-x-3,5-dimethyl(or1-oxo)pyridin-2-yl)methylthio)5-methoxy-1H-benzimidazole where x is a leaving group; oxidation; using titanium complex catalyst and a base
10/16/2008US20080255146 Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy
10/16/2008US20080255129 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics
10/15/2008CN101284819A Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
10/15/2008CN100425609C N-heteroarylnicotinamide derivatives
10/14/2008US7436570 Electrochromic salts, solutions, and devices
10/14/2008US7435832 Preparing an anhydrous crystal of a malic acid salt of N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide by reacting the acid and amine in a solvent and crystallizing under various process conditions
10/14/2008US7435744 Brain disorders; central nervous system disorders; viricides
10/09/2008US20080249319 Process for the preparation of 5-Carboxyphthalide
10/09/2008US20080249110 Novel Substituted 3-Sulfur Indoles
10/09/2008US20080249086 N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}methane-sulfonamide; trial and ventricular arrhythmias; pharmacokinetics; electrophysiological activity; lowering daily clinical dose, lengthening duration of action; side effect reduction; arrhythmia
10/08/2008EP1977749A1 Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
1 ... 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 ... 105